Medical Industry Feature

Guest: Dr. Timothy Craig Hereditary angioedema (HAE) is a rare genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.2 The unpredictability of these attacks is a significant burden on patients.3 Fortunately, preventive treatments like TAKHZYRO® (lanadelumab-flyo) can help reduce the frequency and severity of HAE attacks.1 Here to share key information and data on this treatment option is Dr. Timothy Craig, Professor of Pulmonary, Allergy, and Critical Care Medicine at Pennsylvania State University. IndicationTAKHZYRO® (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age. Important Safety InformationHypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment. Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO wer

Guest: Marc Riedl, MD, MS Prior to 2008, there were limited approved treatment options for hereditary angioedema (HAE) available in the United States, but today, there are several medications approved by the U.S. Food and Drug Administration for preventing and treating HAE attacks.1 In light of the number of therapies that have been approved in recent years and continued clinical advancements in HAE research, what do we need to consider when discussing these treatment options with our patients? Here to share those key considerations and important information on the HAE treatment landscape is Dr. Marc Riedl. References: Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3. ©2022 Takeda Pharmaceutical Company Limited. All rights reserved.US-NON-7747v1.0 09/22